Trial Profile

Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 16 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cabozantinib (Primary)
Indications Renal cell carcinoma
Focus Therapeutic Use
Acronyms Cabo App

Most Recent Events

10 Jun 2021 Status changed from suspended to discontinued.
12 Nov 2020 Planned End Date changed from 1 Sep 2020 to 1 Dec 2021.
12 Nov 2020 Planned primary completion date changed from 1 Sep 2020 to 1 Dec 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com